Mathias V.
- Country
- France
- Department
- gastroenterology
Research Overview
- Comparison of Vedolizumab, Filgotinib, Ustekinumab, and Infliximab as First-Line Advanced Therapy to Maintain Remission in Patients with Ulcerative Colitis
- One-Year Real-World Effectiveness of Subcutaneous Guselkumab in Adults with Crohn’s Disease
- Evaluation of Therapeutic Escalation with Infliximab in Postoperative Recurrence of Crohn's Disease: A Randomized Controlled Trial
Data & Insights
Has run more than one trial at 35 of 115 partner sites.
Specializations
Inflammatory Bowel Disease Management
Specializes in managing Crohn's disease, with particular emphasis on postoperative care and disease recurrence prevention. Investigates therapeutic approaches for patients following ileocolonic anastomosis procedures.
- Postoperative Recurrence Management
- Therapeutic Escalation Strategies
- Endoscopic Assessment
Focuses on developing effective treatment protocols for maintaining disease remission after surgical interventions.
Combination Therapy Approaches
Explores optimal therapeutic combinations for moderate to severe Crohn's disease, evaluating the effectiveness of various immunomodulators when used in conjunction with biological treatments.
- Immunomodulator Combinations
- Biological Therapy Optimization
- Comparative Treatment Efficacy
Investigates the comparative benefits of different combination therapy approaches in achieving endoscopic response.
Novel Therapeutic Applications
Studies innovative treatment options for moderately to severely active Crohn's disease, with particular attention to maintenance therapy regimens using newer therapeutic agents.
- Maintenance Therapy Protocols
- Clinical Remission Strategies
- Endoscopic Response Assessment
Evaluates long-term effectiveness of oral therapeutic agents in maintaining clinical remission.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.